L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 6.8 NOK -0.29% Market Closed
Market Cap: 337.4m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Lytix Biopharma AS
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lytix Biopharma AS
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
L
Lytix Biopharma AS
OSE:LYTIX
Total Receivables
kr12.8m
CAGR 3-Years
45%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Total Receivables
kr28.8m
CAGR 3-Years
37%
CAGR 5-Years
34%
CAGR 10-Years
-5%
B
Bergenbio ASA
OSE:BGBIO
Total Receivables
kr14.5m
CAGR 3-Years
69%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Total Receivables
kr94.8m
CAGR 3-Years
77%
CAGR 5-Years
33%
CAGR 10-Years
24%
N
Nykode Therapeutics ASA
OSE:NYKD
Total Receivables
$3.5m
CAGR 3-Years
-40%
CAGR 5-Years
25%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Total Receivables
kr4.1m
CAGR 3-Years
-50%
CAGR 5-Years
-37%
CAGR 10-Years
-5%
No Stocks Found

Lytix Biopharma AS
Glance View

Market Cap
337.4m NOK
Industry
Biotechnology

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

LYTIX Intrinsic Value
0.9 NOK
Overvaluation 87%
Intrinsic Value
Price
L

See Also

What is Lytix Biopharma AS's Total Receivables?
Total Receivables
12.8m NOK

Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Total Receivables amounts to 12.8m NOK.

What is Lytix Biopharma AS's Total Receivables growth rate?
Total Receivables CAGR 5Y
7%

Over the last year, the Total Receivables growth was 90%. The average annual Total Receivables growth rates for Lytix Biopharma AS have been 45% over the past three years , 7% over the past five years .

Back to Top